Company news

Harmony Biosciences Holdings, Inc. news in 2020

Harmony Biosciences Holdings, Inc.'s news releases, calls and decks from 2020, newest first.

View company

Harmony Biosciences To Be Added To Russell 2000® And Russell 3000® Indexes

December 16, 2020

Harmony Biosciences Enrolls First Patient In Phase 2 Trial Evaluating Pitolisant For Excessive Daytime Sleepiness In Patients With Prader-Willi Syndrome

December 14, 2020

Harmony Biosciences Reports Third Quarter 2020 Financial Results and Business Updates

November 11, 2020

Harmony Biosciences Appoints Mark Graf And Eric Motley To Its Board Of Directors

November 10, 2020

Harmony Biosciences Announces Date Of Third Quarter 2020 Financial Results

October 27, 2020

Harmony Biosciences Receives FDA Approval For Expanded Use Of WAKIX® (pitolisant) For The Treatment Of Cataplexy In Adult Patients With Narcolepsy

October 13, 2020

Harmony Biosciences Announces Recipients Of 2020 Patients At The Heart Grant On Second Annual World Narcolepsy Day

September 21, 2020

Harmony Biosciences Presents Efficacy And Safety Analyses For WAKIX® (pitolisant) At Virtual SLEEP 2020

August 27, 2020

Harmony Biosciences To Present New Data For WAKIX® (pitolisant) At SLEEP 2020 Annual Meeting

August 23, 2020

Harmony Biosciences Announces Closing Of Its Upsized Initial Public Offering And Exercise In Full Of Underwriters' Option To Purchase Additional Shares

August 20, 2020

Harmony Biosciences Announces Pricing Of Upsized Initial Public Offering

August 17, 2020

Decks in 2020